INTRODUCTION

According to cancer statistics in 2020, the global cancer and mortality incidence were approximately 1.8 million and 0.6 million in the United States, respectively. Metastasis and therapeutic resistance are the leading causes of death in cancer patients. Nevertheless, the mechanisms driving poor responses to anticancer treatments remain to be clarified. Therefore, there is an urgent need for elucidating the underlying and intrinsic molecular mechanisms of resistance and for investigating new and effective therapeutic approaches.

MicroRNA (miRNA) are a group of small, non-coding, regulatory RNA with an average length of approximately 22 nucleotides, which mostly modulate gene expression post-transcriptionally through complementary binding to the 3'-untranslated region (3'-UTR) of multiple target genes. Emerging evidence has shown that miRNA are frequently dysregulated in a variety of human malignancies. Among them, microRNA-145 (miR-145) has been increasingly identified as a critical suppressor of carcinogenesis and therapeutic resistance. Resistance to tumor therapy is a challenge in cancer treatment due to the daunting range of resistance mechanisms. We reviewed the status quo of recent advancements in the knowledge of the functional role of miR-145 in therapeutic resistance and the tumor microenvironment. It may serve as an innovative biomarker for therapeutic response and cancer prognosis.
may affect a series of developmental processes by modulating their downstream targeting mRNA expression post-transcriptionally. Among them, microRNA-145 (miR-145) is highly expressed in numerous malignancies and plays a profound role in cancer initiation and therapeutic resistance. In recent five years, accumulating research has focused on the molecular mechanisms of miR-145 mediating the radioresistance and chemoresistance of cancer cells. Researchers are currently attempting to explore the target genes of miR-145 and their signaling pathways involved in altering therapeutic response, which is significant for the development of miRNA-related therapies. Strikingly, various research has disclosed that miR-145 acts in reversion of therapeutic resistance in multiple tumors, including lung cancer, esophageal squamous cell carcinoma (ESCC), ovarian carcinoma, glioma, hepatocellular carcinoma (HCC), breast cancer, colorectal cancer (CRC), prostate cancer, bladder cancer, gastric cancer (GC), pancreatic adenocarcinoma and cervical cancer.

In this review, we summarize the molecular mechanisms and potential pathways involved in the regulation of miR-145, simultaneously focusing on the roles of miR-145 in modulating therapeutic resistance, especially the nature of their intrinsic links across diverse cancers. In addition to its diagnostic or prognostic value, miR-145 can serve as a predictor of chemotherapeutic response.

2 | MIR-145 AND CANCER

Emerging data have indicated that circulating miRNA are diagnostic biomarkers for cancer, dysregulation of which is observed to play a pivotal role in oncogenesis in various cancers. New therapies exploited based on an in-depth understanding of the underlying molecular events in tumor biology are currently high priorities. Numerous recent studies have identified innovative and surrogate miRNA-based biomarkers with predictive or therapeutic potential to reduce patient mortality. miR-145 functions in cancers by regulating its downstream molecules, or being regulated by its upstream RNA molecules, such as long noncoding RNA (lncRNA) and circular RNA (circRNA), both of which have been characterized as "miRNA sponges" and act as competing endogenous RNA (ceRNA). LncRNA-miRNA-mRNA or circRNA-miRNA-mRNA triple network is a significant mechanism of various biological functions of cancer. Herein, miR-145 came into focus as it participated in diverse biological processes of cancers by regulating target genes or signaling, including tumorigenesis, proliferation, differentiation, apoptosis, metastasis, angiogenesis and therapeutic resistance. A sequence of bioinformatics prediction programs, based on mathematical algorithms, have been developed to properly identify mRNA sequences that can serve as a target for each specific miRNA. We used four algorithms to predict and analyze the hypothetical mRNA targets for miR-145, including TargetScan (http://www.targetscan.org), MiRanda (http://www.microrna.org/), MiRDB (http://www.mirdb.org/) and MiRwalks (http://www.mirwalk.umm.uni-heidelberg.de/) (Figure 1). Finally, we screened and identified 78 overlapped potential targets by bioinformatics, which will be helpful in the future research regarding miR-145 (Tables 1 and 2).

3 | MIR-145 IN DRUG RESISTANCE

Drug resistance is a leading reason for therapeutic failure and cancer deaths. Cumulative evidence showed that miR-145 was correlated with chemotherapy resistance, suggesting that it might serve as a candidate and promising biomarker for drug resistance. There are several mechanisms contributing to chemotherapeutic drug resistance, including multidrug resistance (MDR), cancer stem cells (CSC), inhibition of cell death, alterations in the drug target, DNA repair enhancements and gene amplification.

3.1 | Increasing drug efflux

The ATP-binding cassette (ABC) transporter family consists of 49 members, but only 3 have been studied extensively in connection with MDR. These 3 members are: (i) ABC subfamily B member 1 (ABCB1), also known as multidrug resistance protein 1 (MDR1) or P-glycoprotein (P-gp); (ii) ABC subfamily C member 1 (ABCC1), also known as MDR-associated protein 1 (MRP1); and (iii) ABC subfamily G member 2 (ABCG2), also known as breast cancer resistance protein (BCRP) or mitoxantrone-resistance gene (MXR). P-gp is a versatile drug efflux pump, which includes 12 transmembrane domains and two ATP-binding sites. It efficiently removes cytotoxic agents, such as doxorubicin, vinblastine and paclitaxel. Fas ligand (FasL) activation enhances chemotherapy resistance by augmenting the protein expression of P-gp through the ERK1/2 MAPK-GSK3β signaling pathway in CRC and GC. In addition, over-expression of miR-145 could downregulate P-gp as well as hamper FasL-induced upregulation of P-gp.
### TABLE 1
Seventy-eight overlapped potential targets of miR-145 by bioinformatics

| Gene symbol | Gene name |
|-------------|-----------|
| ABCE1       | ATP-binding cassette, sub-family E (OABP), member 1 |
| ABR         | Active BCR-related |
| ACTB        | Actin, beta |
| ADAM19      | ADAM metallopeptidase domain 19 |
| ANO6        | Anoctamin 6 |
| APIG1       | Adaptor-related protein complex 1, gamma 1 subunit |
| ARF6        | ADP-ribosylation factor 6 |
| ARHGAP21    | Rho GTPase activating protein 21 |
| ARHGAP28    | Rho GTPase activating protein 28 |
| ARL11       | ADP-ribosylation factor-like 11 |
| ATP1B4      | ATPase, Na+ + K + transporting, beta 4 polypeptide |
| BTG1        | B-cell translocation gene 1, anti-proliferative |
| CAMK1D      | Calcium/calmodulin-dependent protein kinase ID |
| CAMK2D      | Calcium/calmodulin-dependent protein kinase II delta |
| CAPRIN1     | Cell cycle associated protein 1 |
| CAV2        | Caveolin 2 |
| CTNND1      | Catenin (cadherin-associated protein), delta 1 |
| DERL2       | Derlin 2 |
| DNAL1       | Dynein, axonemal, light chain 1 |
| DYSR1       | Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A |
| ERLIN1      | ER lipid raft associated 1 |
| EXOC8       | Exocyst complex component 8 |
| FAM126A     | Family with sequence similarity 126, member A |
| FBXO34      | F-box protein 34 |
| FLT1        | Fms-related tyrosine kinase 1 |
| GCLM        | Glutamate-cysteine ligase, modifier subunit |
| GRB10       | GRB10 interacting GYF protein 1 |
| HS6ST1      | Heparan sulfate 6-O-sulfotransferase 1 |
| JPH1        | Junctophilin 1 |
| KIF3A       | Kinesin family member 3A |
| KLHL15      | Kelch-like family member 15 |
| KLHL18      | Kelch-like family member 18 |
| LARP4B      | La ribonucleoprotein domain family, member 4B |
| LASP1       | LIM and SH3 protein 1 |
| LIPIN2      | Lipin 2 |
| LRRCC8B     | Leucine rich repeat containing 8 family, member B |
| MPZL1       | Myelin protein zero-like 1 |
| MTX3        | Metaxin 3 |
| NAA25       | N(alpha)-acetyltransferase 25, NatB auxiliary subunit |
| NAA50       | N(alpha)-acetyltransferase 50, NatE catalytic subunit |
| NEDD9       | Neural precursor cell expressed, developmentally down-regulated 9 |
| NR4A2       | Nuclear receptor subfamily 4, group A, member 2 |
| NSUN4       | NOP2/Sun domain family, member 4 |
| NUDT21      | Nudix (nucleoside diphosphate linked moiety X)-type motif 21 |
| NUFIN2      | Nuclear fragile X mental retardation protein interacting protein 2 |
| PAFAH1B2    | Platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 |
| PAN2        | PAN2 poly(A) specific ribonuclease subunit homolog (S. cerevisiae) |
| PHACTR2     | Phosphatase and actin regulator 2 |
| PSAT1       | Phosphoserine aminotransferase 1 |
| PTGFR       | Prostaglandin F receptor (FP) |
| RBM3        | RNA binding motif (RNP1, RM) protein 3 |
| RFX3        | Regulatory factor X, 3 (influences HLA class II expression) |
| RGD3        | RANBP2-like and GRIP domain containing 3 |
| RREB1       | Ras responsive element binding protein 1 |
| RTKN        | Rhotein |
| SEL1L3      | Sel-1 suppressor of lin-12-like 3 (C. elegans) |
| SKP1        | S-phase kinase-associated protein 1 |
| SLC25A25    | Solute carrier family 25 (mitochondrial carrier, phosphate carrier), member 25 |

(Continues)
and NGF transmembrane receptor superfamily, which is capable of activating caspase-dependent apoptosis.46 In addition, miR-145 downregulated P-gp and pRb through inhibition of specificity protein 1 (Sp1) and cyclin-dependent kinase 6 (CDK6), thus promoting sensitivity to paclitaxel in epithelial ovarian cancer (EOC).11 MRP1 is similar to P-gp in structure, and structurally transport a variety of glutathione- and glucuronide-conjugated molecules.41,42 Intriguingly, overexpression of miR-145 could enhance chemotherapeutic efficiency through inducing intracellular doxorubicin accumulation by suppressing MRP1 in breast cancer.17 MiR-145 sensitized ESCC to cisplatin by directly inhibiting the PI3K/AKT signaling axis, which, in turn, led to a decrease of MRP1 and P-gp expression.7 Analogously, miR-145 inhibited oxaliplatin resistance in CRC by regulating G protein coupled receptor 98 (GPR98), thus downregulating MRP1 and P-gp.15 LINC00707 enhanced the expression of MRP1 and P-gp by sponging miR-145 in non–small cell lung cancer (NSCLC). Moreover, knockdown of LINC00707 suppressed expression of anti–apoptotic protein BCL-2 and enhanced expression of pro–apoptotic protein Bax, thus promoting cisplatin sensitivity.4 LINC0071 contributed to cisplatin and pemetrexed resistance in lung adenocarcinoma by positively regulating MRP1 through sponging miR-145.3 Analogously, IncRNA CACSI1 contributed to oxaliplatin resistance in CRC cancer through the miR-145/MRP1 axis.18 The MiR-145/MRP1 axis also increased cisplatin toxicity in gallbladder cancer.6,3 TGF-β1 contributed to MDR in HCC through increasing the expression of P-gp and BCRP via the SMAD4/IncRNA HOX transcript antisense RNA (HOTAIR)/miR-145 axis. TGF-β signals are transduced by the SMAD family that regulates homeostasis, proliferation, apoptosis, differentiation and tumor growth. SMAD4 functions as a shuttle between the cytoplasm and the nucleus, whose gene is located on the long arm of chromosome 18 at point 21.14,44,45 (Figure 2).

### 3.2 Inhibition of apoptosis

Apoptosis is the program of cell death that may be triggered via numerous internal mitochondria-mediated signaling pathways (eg, BCL-2 and Bax) or external receptor-dependent stimulus (eg, FAS, TNF-R and caspases-3, -6, -7 and -8).46 Overexpression of miR-145 obviously blocked cell viability and facilitated the cell apoptosis rate upon 5-fluorouracil (5-FU) treatment through downregulation of reverseless 3-like (REV3L) in ESCC. Meanwhile, miR-145 was more efficient in modulating apoptotic proteins, whose overexpression induced a prominent decrease of BCL-2 expression and an increase of Bax and cleaved caspase-3 expression, thus activating pro–apoptotic activity.8,47 As the catalytic subunit of DNA polymerase ζ, REV3L is overexpressed and mutated in several cancers and has been validated as a contributor of chemotherapy resistance.48-50 MiR-145-3p enhanced bortezomib sensitivity by targeting histone deacetylase 4 (HDAC4) in multiple myeloma. Furthermore, suppression of HDAC4 upregulated pro–apoptotic protein BCL2L11 and caused MTORC1 inactivation, thereby promoting autophagy and cell death. Histone deacetylases control a broad array of tumor biological processes, such as apoptosis, survival and autophagy.51,52 MiR-145 enhanced cell sensitivity to cetuximab by stimulating cetuximab-mediated antibody-dependent cellular cytotoxicity (ADCC) in colon cancer. Elevated apoptosis was observed during ADCC, which could be explained partly by the reduced BCL-2, increased caspase-3/7 and granzyme B activity. Granzyme B can target both cytosolic and nuclear substrates to induce apoptosis, and its most distinguished function is the direct cleavage of caspase-3.53,54 Nuclear factor-κB (NF-κB) is a prosurvival transcription factor, whose transcriptional targets are anti–apoptotic proteins. APRIL attenuated therapeutic efficacy via activation of the NF-κB pathway in GC, whose expression was regulated by miR-145. APRIL, a member of the TNF family, was reported to function in sustaining lymphocytic leukemia B cell survival. MiR-145 represented a therapeutic target to overcome chemotherapeutic resistance, which reversed APRIL-mediated cisplatin resistance via directly targeting its 3’-untranslated region (3’-UTR).26,55

| Gene symbol | Gene name |
|-------------|-----------|
| SMCR8       | Smith-Magenis syndrome chromosome region, candidate 8 |
| SNX24       | Sorting nexin 24 |
| SNX27       | Sorting nexin 27 |
| SOCS7       | Suppressor of cytokine signaling 7 |
| SRGAP1      | SLIT-ROBO Rho GTPase activating protein 1 |
| STAM        | Signal transducing adaptor molecule (SH3 domain and ITAM motif) 1 |
| TAGLN2      | Transgelin 2 |
| TBPL1       | TBP-like 1 |
| TET2        | Tet methylcytosine dioxygenase 2 |
| TGFBR2      | Transforming growth factor, beta receptor II (70/80kDa) |
| TM9SF4      | Transmembrane 9 superfamily protein member 4 |
| TMOD1       | Tropomodulin 1 |
| TMOD3       | Tropomodulin 3 |
| TPM3        | Tropomyosin 3 |
| TPM4        | Tropomyosin 4 |
| TSPAN6      | Tetraspanin 6 |
| TTC14       | Tetratricopeptide repeat domain 14 |
| USP31       | Ubiquitin specific peptidase 31 |
| ZBTB33      | Zinc finger and BTB domain containing 33 |
| ZNF521      | Zinc finger protein 521 |

(Continued)
3.3 Cancer stem cells

Emerging data showed that CSC represented a small subpopulation of cells within most solid and hematologic cancers, and were vital mediators and drivers in chemotherapy and radiation resistance.\textsuperscript{56–58} MiR-145 provided a therapeutic scheme to inhibit the CSC-like properties of GC, and lowered 5-FU and cisplatin chemoresistance by targeting CD44, an integral cell membrane glycoprotein.\textsuperscript{25} CD44 is a helpful CSC marker for verifying and isolating CSC from a panel of gastric cancer cell lines, and may be a driving factor in the evolution of CSC.\textsuperscript{59–61} Wnt signaling is a crucial CSC self-renewal signaling pathway.\textsuperscript{62} MiR-145 enhanced chemosensitivity to demethoxycurcumin by targeting the SOX2-Wnt/\(\beta\)-catenin axis in glioma. SOX2, a pluripotent stem cell marker, plays a pivotal role in maintaining the undifferentiated situation and proliferation of stem cells.\textsuperscript{12} CREB-binding protein (CBP) is a Wnt signaling component, and is frequently activated in nasopharyngeal carcinoma. A specific CBP/\(\beta\)-catenin antagonist was identified to repress the CSC-like population through restoration of miR-145, which directly targeted SOX2. Moreover, it effectively suppressed the growth of nasopharyngeal carcinoma when combined with cisplatin.\textsuperscript{63} The elevated TGF-\(\beta\) induced a regulatory axis of lncRNA-LET/NF90/miR-145 to increase CSC populations and promote gemcitabine resistance through upregulation of stemness markers HMGA2 and KLF4 in bladder cancer.\textsuperscript{24} Kruppel-like factor 4 (KLF4) is a transcription factor expressed

| Tumor                        | Target(s)                  | Therapeutic agents                  | References                                                                 |
|------------------------------|----------------------------|-------------------------------------|----------------------------------------------------------------------------|
| NSCLC                        | ADAM19                     | Gefitinib                           | Wang et al\textsuperscript{5}                                              |
|                              | EGFR                       | Erlotinib                            | Amri et al\textsuperscript{6}                                              |
|                              | MRP1 and P-gp              | Cisplatin                           | Zhang et al\textsuperscript{4}                                             |
|                              | CDK6                       | Cisplatin                           | Bar et al\textsuperscript{76}                                             |
|                              | KLF4                       | Cisplatin                           | Cui et al\textsuperscript{65}                                             |
| Lung adenocarcinoma          | FSCN1                      | Docetaxel                           | Pan et al\textsuperscript{69}                                             |
|                              | MRP1                       | Cisplatin and pemetrexed            | Zheng et al\textsuperscript{3}                                             |
| CRC                          | GPR98                      | Oxaliplatin                         | Fu et al\textsuperscript{19}                                              |
|                              | MRP1                       | Oxaliplatin                         | Gao et al\textsuperscript{18}                                             |
|                              | RAD18                      | 5-FU                                | Liu et al\textsuperscript{20}                                             |
|                              | KLF4 and c-Myc             | Radiation                           | Zhu et al\textsuperscript{9}                                              |
| Colon cancer                 | OCT4, SOX2, Nanog          | Cisplatin and paclitaxel            | Yan et al\textsuperscript{64}                                             |
| CRC and GC                   | P-gp                       | 5-FU, SN38, or Oxaliplatin          | Zheng et al\textsuperscript{39}                                           |
| GC                           | APRIL                      | Cisplatin                           | Zhi et al\textsuperscript{26,55}                                         |
|                              | CD44                       | 5-FU and cisplatin                  | Zeng et al\textsuperscript{25}                                            |
| HCC                          | P-gp and BCRP              | Imatinib                            | Kong et al\textsuperscript{14}                                            |
|                              | RAD18                      | Radiation                           | Chen et al\textsuperscript{16}                                            |
|                              | SMAD3                      | Doxorubicin                         | Ju et al\textsuperscript{37}                                              |
| Esophageal carcinoma         | MRP1 and P-gp              | Cisplatin                           | Zheng et al\textsuperscript{39}                                           |
|                              | REV3L                      | 5-FU                                | Chen et al\textsuperscript{8}                                             |
|                              | P70S6K1                    | Radiation                           | Wang et al\textsuperscript{88}                                            |
| Ovarian cancer               | Sp1 and CDK6               | Paclitaxel                          | Zhu et al\textsuperscript{11}                                             |
|                              | c-Myc                      | Cisplatin                           | Sheng et al\textsuperscript{10}                                           |
| Cervical cancer              | HLTF                       | Radiation                           | Ye et al\textsuperscript{28}                                              |
| Breast cancer                | MRP1                       | Doxorubicin                         | Gao et al\textsuperscript{17}                                             |
| Prostate cancer              | AKAP12                     | Docetaxel                           | Xue et al\textsuperscript{22}                                             |
|                              | RAD51, Mcl1, Par-4 and PARP1| Radiation                           | Gong et al\textsuperscript{23}                                            |
| Bladder cancer               | HMGA2 and KLF4             | Gemcitabine                         | Zhuang et al\textsuperscript{44}                                          |
| Pancreatic Adenocarcinoma     | P70S6K1                    | Gemcitabine                         | Lin et al\textsuperscript{27}                                             |
| Gallbladder cancer           | MRP1                       | Cisplatin                           | Zhan et al\textsuperscript{43,59}                                        |
| Nasopharyngeal carcinoma     | SOX2                       | Cisplatin                           | Chan et al\textsuperscript{63}                                            |
| Multiple myeloma             | HDAC4                      | Bortezomib                          | Wu et al\textsuperscript{51}                                              |

Note: CRC, colorectal cancer; GC, gastric cancer; HCC, hepatocellular carcinoma; NSCLC, non-small-cell lung cancer

TABLE 2 Summary of target genes and therapeutic agents of miR-145 in cancer therapy resistance
in various human tissues, which controls cell reprogramming and sustains stemness maintenance. LncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) contributed to cisplatin resistance by regulating the miR-145/KLF4 axis in NSCLC. Likewise, lncRNA ROR sponged miR-145 to prevent OCT4, SOX2, and Nanog in colon CSC, thereby increasing the stem cell phenotype, and then enhanced chemoresistance to cisplatin and paclitaxel (Figure 3).

3.4 | Other mechanisms

Other mechanisms engaged in chemotherapy resistance and impairing therapy efficacy mainly involve epithelial–mesenchymal transition (EMT), metabolic changes, DNA damage repair and immune tolerance. EMT is a universal phenomenon in cancers, in which epithelial cells are transformed into a mesenchymal phenotype. Furthermore, EMT is verified to participate in the drug
resistance of cancer cells. The LncRNA ROR/miR-145/FSCN1 axis effectively reversed EMT in docetaxel-resistant lung adenocarcinoma cells and sensitized them to chemotherapy. MIR-145 increased the doxorubicin cytotoxicity in chemoresistant tumor cells via EMT through downregulating SMAD3 in HCC. SMAD3, another member of the SMAD family, serves as a substrate for TGF-β and commonly called receptor-regulated SMAD. Tumor suppressor miR-145 reversed 5-FU resistance by directly targeting DNA damage-related gene RAD18 in CRC. RAD18, a DNA damage-activated E3 ubiquitin ligase, is known to play a critical role in DNA damage repair in cancer cells. MIR-145 increased the sensitivity of pancreatic adenocarcinoma cells to gemcitabine treatment, providing new insight into the role of miR-145/P70S6K1/HIF-1α/VEGF in mediating gemcitabine chemosensitivity. Hypoxia-inducible factor 1 (HIF1), a critical player in the Warburg effect, binds to hypoxia response elements on DNA and stimulates VEGF gene transcription. In addition, emerging evidence has shown that the Warburg effect promotes drug resistance. Accumulating studies have reported the activation of EGFR as a resistance mechanism to chemotherapy. Targeting EGFR by miR-145 inhibited cell growth and sensitized NSCLC cells to erlotinib. LncRNA MALAT1 enhanced the docetaxel resistance of prostate cancer cells via miR-145-5p-mediated regulation of AKAP12. MIR-145 enhanced the sensitivity of NSCLC to gefitinib through targeting ADAM19. A disintegrin and metalloproteinases (ADAMs) are zinc-dependent, membrane-associated metalloproteinases. ADAM19 is known to be involved in extracellular matrix breakdown and catalytically mediated ectodomain shedding of substrates such as TNF-α. CDK6 was identified as a potential miR-145 target and cispalatin sensitivity mediator in NSCLC. Notably, this suggested that the inhibitor of CDK4/6 should be avoided during cisplatin therapy. Immune tolerance is one of the leading causes of chemotherapy resistance in carcinoma cases. Programmed death-ligand 1 (PD-L1) is an inhibitory molecule expressed by cancer cells, which plays a significant role in immune tolerance through the induction of T cell dysfunction. The MiR-145/c-Myc/PD-L1 axis contributed to cisplatin resistance in ovarian cancer.

4 | MIR-145 IN RADIOTHERAPY RESISTANCE

Ionizing radiation (IR) induces a complicated cellular reaction involving affluent molecular pathways. MIR-145 was also shown to function in mediating resistance to the cytotoxic action of IR. DNA repair enzymes and anti-apoptotic proteins were highly expressed in radio-resistant cancer cells. MIR-145 appeared to dramatically sensitized cancer cells to radiation by reducing the efficiency of the repair of radiation-induced DNA double-strand breaks. Certainly, we need to further study this to determine more specific mechanisms of the radiosensitizing effect of miR-145. Elevated expression of miR-145 contributed to promoting radiosensitivity of prostate cancer, potentially by downregulating DNA repair via targeting Par-4, PARP, RAD51 and Mcl-1. Mitotic catastrophe was dramatically increased in cells receiving miR-145 and radiation. Par-4, a pro-apoptotic gene, repressed radiation-induced NF-κB activity and BCL-2 expression, resulting in an increase of radiosensitivity in prostate cancer. PARP1 played a profound role in the repair of radiation-induced DNA damage, indicating its inhibition might serve as a promising mechanism for promoting radiosensitivity. Downregulation of RAD51 gene expression was reported to enhance sensitivity to gamma radiation in glioma, while the Mcl-1 enhanced radiosensitivity of pancreatic carcinoma in vitro. CSC phenotype and EMT cooperated to impact therapeutically resistant in epithelial tumors such as CRC. The zinc finger molecule snail family transcriptional repressor 1 (SNAI1) is a transcriptional factor that plays a critical role in provoking EMT.

5 | CONCLUSIONS AND PROSPECTS

Chemotherapy and radiotherapy are critical treatment strategies for cancer patients. These strategies are occasionally insufficient to improve poor prognosis due to therapeutic resistance. Cancers are sophisticated, dynamic systems that start to evolve resistance strategies immediately with the application of therapies. Remaining tumor cells become therapy-resistant in some patients over the duration of treatment, resulting in relapse and metastasis. Resistance to chemotherapy and radiotherapy is a major obstacle facing current cancer research. Numerous mechanisms may be involved in the therapeutic resistance of cancer, among which miR-145 plays a pivotal role in the acquisition of therapeutic resistance indicated by accumulating evidence. The aforementioned discussion...
disclosed the latent role of miR-145 as both a predictive marker of response and a new therapeutic target, which could further enhance the efficacy of chemotherapy and radiotherapy. Collectively, developing successful therapeutic strategies will require scientists to identify and comprehend the resistance-inhibiting effects of miR-145. Given their intrinsic properties, miR-145 could serve as a novel biomarker and promising therapeutic target for cancer, and may provide new insights into the diagnosis of patients at early stages, prediction of prognosis, and screening of the patients in response to therapy, although further investigation is required before application in the clinic.

ACKNOWLEDGMENTS
This work was supported by the National Key Research and Development Program of China (No. 2016YFC0905900), the National Natural Science Foundation of China (No. 81872365) and Jiangsu Provincial Key Research Development Program (No. BE2019731).

CONFLICT OF INTEREST
The authors have no conflict of interest.

ORCID
Jinhai Tang https://orcid.org/0000-0003-2016-4216

REFERENCES
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7-30.
2. Dweep H, Gretz N. miRWalk2.0: a comprehensive atlas of microRNA-target interactions. Nat Methods. 2015;12:697.
3. Zheng F, Xu R. CircPVT1 contributes to chemotherapy resistance of lung adenocarcinoma through miR-145-5p/ABCC1 axis. Biomed Pharmacother. 2020;124:109628.
4. Zhang H, Luo Y, Xu W, Li K, Liao C. Silencing long intergenic non-coding RNA 00707 enhances cisplatin sensitivity in cisplatin-resistant non-small-cell lung cancer cells by sponging miR-145. Oncol Lett. 2019;18:6261-6268.
5. Wang Y, Lian YM, Ge CY. miR-145 changes sensitivity of non-small cell lung cancer to gefitinib through targeting ADAM19. Eur Rev Med Pharmacol Sci. 2019;23:5831-5839.
6. Amri J, Molaei N, Baazm M, Karami H. Targeting epidermal growth factor receptor by miRNA-145 inhibits cell growth and sensitizes NSCLC cells to Erlotinib. Asian Pac J Cancer Prevent. 2019;20:2781-2787.
7. Zheng T-L, Li D-P, He Z-F, Zhao S. miR-145 sensitizes esophageal squamous cell carcinoma to cisplatin through directly inhibiting PI3K/AKT signaling pathway. Cancer Cell Int. 2019;19:250.
8. Chen Q, Hou J, Wu Z, Zhao J, Ma D. miR-145 Regulates the sensitivity of esophageal squamous cell carcinoma cells to 5-FU via targeting REV3L. Pathol Res Pract. 2019;215:152427.
9. Zhu Y, Wang C, Becker SA, et al. miR-145 antagonizes SNAI1-mediated stemness and radiation resistance in colorectal cancer. Mol Ther. 2018;26:744-754.
10. Sheng Q, Zhang Y, Wang Z, Ding J, Song Y, Zhao W. Cisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells. Clin Exp Immunol. 2020;200:45-52.
11. Zhu X, Li Y, Xie C, et al. miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6. Int J Cancer. 2014;135:1286-1296.
12. Qian C, Wang B, Zou Y, et al. MicroRNA-145 enhances chemosensitivity of glioblastoma stem cells to temozolomycin. Cancer Manag Res. 2019;11:6829-6840.
13. Hua L, Huang L, Zhang X, Feng H, Shen B. Knockdown of circular RNA CEP128 suppresses proliferation and improves cytotoxic efficacy of temozolomide in glioma cells by regulating miR-145-5p. NeuroReport. 2019;30:1231-1238.
14. Kong J, Qiu Y, Li Y, Zhang H, Wang W. TGF-β1 elevates P-gpo and BCRP in hepatocellular carcinoma through HOTAIR/miR-145 axis. Biopharm Drug Dispos. 2019;40:70-80.
15. Ju BL, Chen YB, Zhang WY, Yu CH, Zhu DQ, Jin J. miR-145 regulates chemoresistance in hepatocellular carcinoma via epithelial mesenchymal transition. Cell Mol Biol. 2015;61:12-16.
16. Chen Y, Shen Z, Zhi Y, et al. Long non-coding RNA ROR promotes radioresistance in hepatocellular carcinoma cells by acting as a ceRNA for microRNA-145 to regulate RAD18 expression. Arch Biochem Biophys. 2018;645:117-125.
17. Gao M, Miao L, Liu M, et al. miR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1. Oncotarget. 2016;7:59714-59726.
18. Gao R, Fang C, Xu J, Tan H, Li P, Ma L. LncRNA CAC515 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145. Arch Biochem Biophys. 2019;663:183-191.
19. Fu Q, Cheng J, Zhang J, et al. MiR-145 inhibits drug resistance to Oxaliplatin in colorectal cancer cells through regulating G protein coupled receptor 98. Zhonghua Wei Chang Wai Ke Za Zhi. 2017;20:566-570.
20. Liu R-L, Dong Y, Deng Y-Z, Wang W-J, Li W-D. Tumor suppressor miR-145 reverses drug resistance by targeting directly DNA damage-related gene RAD18 in colorectal cancer. Tumour Biol. 2015;36:5011-5019.
21. Yang P, Yang Y, An W, et al. The long non-coding RNA-ROR promotes the resistance of radiotherapy for human colorectal cancer cells by targeting the p53/miR-145 pathway. J Gastroenterol Hepatol. 2017;32:837-845.
22. Xue D, Lu H, Xu H-Y, Zhou C-X, He X-Z. Long noncoding RNA MALAT1 enhances the docetaxel resistance of prostate cancer cells via miR-145-5p-mediated regulation of AKAP12. J Cell Mol Med. 2018;22:3223-3237.
23. Gong P, Zhang T, He D, Hsieh J-T. MicroRNA-145 modulates tumor sensitivity to radiation in prostate cancer. Radiat Res. 2018;184:630-638.
24. Zhuang J, Shen L, Yang L, et al. TGFβ1 promotes gemcitabine resistance through regulating the LncRNA-LET/NF90/miR-145 signaling axis in bladder cancer. Theranostics. 2017;7:3053-3067.
25. Zeng J-F, Ma X-Q, Wang L-P, Wang W. MicroRNA-145 experts tumor-suppressive and chemoresistance lowering effects by targeting CD44 in gastric cancer. World J Gastroenterol. 2017;23:2337-2345.
26. Zhi X, Tao J, Xiang G, et al. APRIL induces cisplatin resistance in gastric cancer cells via activation of the NF-κB pathway. Cell Physiol Biochem. 2019;40:70-80.
27. Yin Y, Li Y, Yen W, et al. MiRNA-145 increases therapeutic sensitivity of gemcitabine treatment of pancreatic adenocarcinoma cells. Oncotarget. 2016;7:70857-70868.
30. Lin XJ, Chong Y, Guo ZW, et al. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. Lancet Oncol. 2015;16:804-815.

31. Mohammadi M, Goodarzi M, Jaafari MR, Mirzaei HR, Mirzeai H. Circulating microRNA: a new candidate for diagnostic biomarker in neuroblastoma. Cancer Gene Ther. 2016;23:371-372.

32. Fumagalli C, Bianchi F, Raviele PR, et al. Circulating and tissue biomarkers in early-stage non-small cell lung cancer. Cancermedicalsce, 2017;11:717.

33. Shang X, Li G, Liu H, et al. Comprehensive circular RNA profiling reveals that hsa_circ_0005075, a new circular rna biomarker, is involved in hepatocellular carcinoma development. Medicine. 2016;95:e3811.

34. Zhang F, Zhang R, Zhang X, et al. Comprehensive analysis of circRNA expression pattern and circRNA-miRNA-mRNA network in the pathogenesis of atherosclerosis in rabbits. Aging. 2018;10:2266-2283.

35. Mansoori B, Mohammadi A, Davudian S, Shirjarg S, Baradaran B. The different mechanisms of cancer drug resistance: a brief review. Adv Pharm Bull. 2017;7:339-348.

36. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13:714-726.

37. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2:48-58.

38. Chen CJ, Chin JE, Ueda K, et al. Internal duplication and homology. Loe DW, Deeley RG, Cole SP. Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Can Res. 1998;58:5130-5136.

39. Zheng H, Liu Z, Liu T, et al. Fas signaling promotes chemoresistance in gastrointestinal cancer by up-regulating P-glycoprotein. Oncotarget. 2014;5:10763-10777.

40. Curtin JF, Cotter TG. Live and let die: regulatory mechanisms in Fas-mediated apoptosis. Cell Signal. 2003;15:983-992.

41. Roe DW, Dellely RG, Cole SP. Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Can Res. 1998;58:5130-5136.

42. Müller M, Meijer C, Zaman GJ, et al. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci U S A. 1994;91:13033-13037.

43. Zhan M, Zhao X, Wang H, et al. miR-145 sensitizes gallbladder cancer to cisplatin by regulating multidrug resistance associated protein 1. Tumour Biol. 2016;37:10553-10562.

44. Ullah I, Sun W, Tang L, Feng J. Roles of Smads family and alternative splicing variants of Smad4 in different cancers. J Cancer. 2018;9:4018-4028.

45. Singh P, Wig JD, Srinivasan R. The Smad family and its role in pancreatic cancer. Indian J Cancer. 2011;48:351-360.

46. Castro L, Gao X, Moore AB, et al. A high concentration of genistein induces cell death in human uterine leiomyoma cells by autophagy. Expert Opin Environ Biol. 2016;5. https://doi.org/10.1017/2325-9655.51-003

47. Alnemri ES, Livingston DJ, Nicholson DW, et al. Human ICE/CED-3 protease nomenclature. Cell. 1996;87:171.

48. Wang J, Liu Q, Yuan S, et al. Genetic predisposition to lung cancer: comprehensive literature integration, meta-analysis, and multiple evidence assessment of candidate-gene association studies. Sci Rep. 2017;7:8371.

49. Jiang HG, Chen P, Su JY, et al. Knockdown of REV3 synergizes with ATR inhibition to promote apoptosis induced by cisplatin in lung cancer cells. J Cell Physiol. 2017;232:3433-3443.

50. Huang KK, Jang KW, Kim S, et al. Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck. Sci Rep. 2016;6:19552.

51. Wu H, Liu C, Yang Q, et al. MIR145-3p promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting HDAC4. Autophagy. 2020;16:683-697.

52. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene. 2007;26:5420-5432.

53. Gomes SE, Simões AES, Pereira DM, Castro RE, Rodrigues CMP, Borralho PM, mir-143 or mir-145 overexpression increases cetu- imab-mediated antibody-dependent cellular cytotoxicity in human colon cancer cells. Oncotarget. 2016;7:9368-9387.

54. Boivin WA, Cooper DM, Hiebert PR, Granville DJ. Intracellular versus extracellular granzyme B in immunity and disease: challenging the dogma. Lab Investig. 2009;89:1195-1220.

55. Zhi X, Tao J, Xiang G, et al. APRIL induces cisplatin resistance in gastric cancer cells via activation of the NF-kappaB pathway. Cell Physiol Biochem. 2015;35:571-585.

56. O’Brien CA, Kreso A, Dick JE. Cancer stem cells in solid tumors: an overview. Semin Radiat Oncol. 2009;19:71-77.

57. Morrison R, Schleicher SM, Sun Y, et al. Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. J Oncol. 2011;2011:941876.

58. Chang JC. Cancer stem cells: Role in tumor growth, recurrence, metastasis, and treatment resistance. Medicine. 2016;95(1 Suppl 1):S20-S25.

59. Zhang X, Hua R, Wang X, et al. Identification of stem-like cells and clinical significance of candidate stem cell markers in gastric cancer. Oncotarget. 2016;7:9815-9831.

60. Chen W, Zhang X, Chu C, et al. Identification of CD44+ cancer stem cells in human gastric cancer. Hepatogastroenterology. 2013;60:949-954.

61. Bhatavakar DM, Patel DD, Chikhlikar PR, et al. Overexpression of CD44: a useful independent predictor of prognosis in patients with colorectal carcinomas. Ann Surg Oncol. 1998;5:495-501.

62. Takahashi-Yanaga F, Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res. 2010;16:3153-3162.

63. Chan KC, Chan LS, Ip JCY, et al. Therapeutic targeting of CBP/β-catenin signaling reduces cancer stem-like population and syn- ergistically suppresses growth of EBV-positive nasopharyngeal carcinoma cells with cisplatin. Sci Rep. 2015;5:9979.

64. Fadous-Khalifé MC, Aloulou N, Jalbout M, et al. Krüppel-like factor 4: A new potential biomarker of lung cancer. Mol Clin Oncol. 2016;5:35-40.

65. Cui Y, Li G, Zhang X, Dai F, Zhang R. Increased MALAT1 expression contributes to cisplatin resistance in non-small cell lung cancer. Oncol Letters. 2018;16:4821-4828.

66. Yan ZY, Sun XC. [LincRNA-ROR functions as a ceRNA to regulate Oct4, Sox2, and Nanog expression by sponging miR-145 and its ef- ect on biologic characteristics of colonic cancer stem cells]. Chinese J Pathol. 2018;47:284-290.

67. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal tran- sition. J Clin Investig. 2009;119:1420-1428.

68. Neel DS, Bivona TG. Secrets of drug resistance in NSCLC exposed by new molecular definition of EMT. Clin Cancer Res. 2013;19:3-5.

69. Pan Y, Chen J, Tao L, et al. Long noncoding RNA ROR regulates chemoresistance in docetaxel-resistant lung adenocarcinoma cells via epithelial mesenchymal transition pathway. Oncotarget. 2017;8:33144-33158.

70. Zhang H, Du L, Zhong Y, Flanders KC, Roberts JD Jr. Transforming growth factor-β stimulates Smad1/5 signaling in pulmonary artery smooth muscle cells and fibroblasts of the newborn mouse through ALK1. Am J Physiol Lung Cell Mol Physiol. 2017;313:L615-L627.
71. Icard P, Shulman S, Farhat D, Steyaert JM, Alifano M, Linet H. How the Warburg effect supports aggressiveness and drug resistance of cancer cells? Drug Resist Updates. 2018;38:1-11.
72. Boufraquech M, Zhang L, Jain M, et al. miR-145 suppresses thyroid cancer growth and metastasis and targets AKT3. Endocr Relat Cancer. 2014;21:517-531.
73. Sumitomo M, Asano T, Asakuma J, Asano T, Horiguchi A, Hayakawa M. ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway. Clin Cancer Res. 2004;10:794-801.
74. Van Schaeybroeck S, Karaiskou-McCaul A, Kelly D, et al. Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin Cancer Res. 2005;11:7480-7489.
75. Wei P, Zhao YG, Zhuang L, Ruben S, Sang QX. Expression and enzymatic activity of human disintegrin and metalloproteinase ADAM19/meltrin beta. Biochem Biophys Res Comm. 2001;280:744-755.
76. Bar J, Gorn-Hondermann I, Moretto P, et al. miR Profiling Identifies Cyclin-Dependent Kinase 6 Downregulation as a Potential Mechanism of Acquired Cisplatin Resistance in Non-Small-Cell Lung Carcinoma. Clin Lung Cancer. 2015;16:e121-e129.
77. Ghisolfi L, Keates AC, Hu X, Lee DK, Li CJ. Ionizing radiation induces stemness in cancer cells. PLoS One. 2012;7:e43628.
78. Chendil D, Das A, Dey S, Mohiuddin M, Ahmed MM. Par-4, a pro-apoptotic gene, inhibits radiation-induced NF kappa B activity and Bcl-2 expression leading to induction of radiosensitivity in human prostate cancer cells PC-3. Cancer Biol Ther. 2002;1:152-160.
79. Pacchierotti F, Ranaldi R, Derijck AA, van der Heijden GW, de Boer P. In vivo repair of DNA damage induced by X-rays in the early stages of mouse fertilization, and the influence of maternal PARP1 ablation. Mutat Res. 2011;714:44-52.
80. Olaussen KA, Adam J, Vanhecke E, et al. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs. Lung Cancer. 2013;80:216-222.
81. Ohnishi T, Taki T, Hiraga S, Arita N, Morita T. In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene. Biochem Biophys Res Comm. 1998;245:319-324.
82. Guoan X, Hanning W, Kaiyun C, Hao L. Adenovirus-mediated siRNA targeting Mcl-1 gene increases radiosensitivity of pancreatic carcinoma cells in vitro and in vivo. Surgery. 2010;147:553-561.
83. Sachdeva M, Liu Q, Cao J, Lu Z, Mo Y-Y. Negative regulation of miR-145 by C/EBP-β through the Akt pathway in cancer cells. Nucleic Acids Res. 2012;40:6683-6692.
84. Wang M, Wang L, He X, et al. IncRNA CCAT2 promotes radiotherapy resistance for human esophageal carcinoma cells via the miR-145/p70S6K1 and p53 pathway. Int J Oncol. 2020;56:327-336.
85. Kibria G, Hatakeyama H, Harashima H. Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system. Arch Pharm Res. 2014;37:4-15.

How to cite this article: Xu W, Hua Y, Deng F, et al. MiR-145 in cancer therapy resistance and sensitivity: A comprehensive review. Cancer Sci. 2020;111:3122–3131. https://doi.org/10.1111/cas.14517